Physiologic Pacing for First-Degree Heart Block
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if physiologic pacing, a type of cardiac pacing, can improve symptoms and outcomes for individuals with symptomatic first-degree heart block. In this condition, the heart's electrical signals move more slowly than usual, and participants should have a PR interval of 250ms or more, as shown on an ECG. The trial will compare two different pacing methods to identify the most effective one. Suitable candidates for this trial experience symptoms affecting daily life due to heart block and meet specific heart function criteria. As an unphased trial, it offers participants the chance to contribute to pioneering research that could enhance heart block treatments.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that physiologic pacing is safe for patients with first-degree heart block?
Research has shown that physiologic pacing, which includes His Bundle Pacing (HBP) and Left Bundle Branch Area Pacing (LBBAP), is generally well-tolerated by patients. Previous studies have examined the effectiveness and safety of these methods. One study found that physiologic pacing, including HBP and LBBAP, was safe and effective for most patients, causing no major problems. Another study compared different pacing methods and found that both LBBAP and HBP produced good results without significant safety issues. These findings suggest that physiologic pacing is a safe option for patients, with no major adverse events reported in the research.12345
Why are researchers excited about this trial?
Researchers are excited about physiologic pacing for first-degree heart block because it offers a more tailored approach to managing heart rhythms. Unlike traditional pacing methods that might not fully respect the heart's natural timing, physiologic pacing aims to closely mimic the heart's normal electrical activity. This approach could lead to better heart function and fewer complications over time. By switching between AAI-DDD-50 and DDD-50 programming, this method explores optimizing pacing strategies to improve patient outcomes, offering a potential breakthrough in personalized cardiac care.
What evidence suggests that physiologic pacing is effective for first-degree heart block?
Research has shown that a special type of heart pacing, called physiologic pacing, can improve heart function in people with certain heart conditions. Specifically, two methods—His Bundle Pacing and Left Bundle Branch Pacing—have proven more effective than traditional methods. These methods can enhance heart performance and reduce symptoms. In this trial, participants will be assigned to different pacing sequences, such as AAI-DDD 50 followed by DDD-50, or DDD-50 followed by AAI-DDD 50, to evaluate the effectiveness of physiologic pacing for first-degree heart block. For people with heart failure and left bundle branch block, physiologic pacing has resulted in better long-term outcomes. This suggests that physiologic pacing might also benefit those with first-degree heart block by improving heart function.26789
Are You a Good Fit for This Trial?
This trial is for individuals with symptomatic first-degree heart block, which means their hearts have a specific type of electrical delay. Participants must meet certain health criteria to join, but the provided information does not specify these details.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Evaluation
Patients are evaluated for baseline symptoms, exercise capacity, arrhythmia burden, and patient activity
Treatment
Patients undergo left bundle pacing and are randomized to DDD-50 vs MVP-50 with a crossover at 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment, including quality of life, exercise capacity, patient activity, and atrial fibrillation burden
What Are the Treatments Tested in This Trial?
Interventions
- Physiologic Pacing
Physiologic Pacing is already approved in European Union, United States for the following indications:
- Heart failure
- Symptomatic first-degree heart block
- High-grade AV block
- Complete heart block
- Heart failure
- Symptomatic first-degree heart block
- High-grade AV block
- Complete heart block
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ascension Health
Lead Sponsor
Medtronic
Industry Sponsor
Geoff Martha
Medtronic
Chief Executive Officer since 2020
Finance degree from Penn State University
Dr. Richard Kuntz
Medtronic
Chief Medical Officer since 2023
MD, MSc